ScreenPoint Medical has raised US$28 million in a Series C investment round led by Insight Partners
Netherlands-based ScreenPoint Medical, an AI technology company that develops advanced image recognition and machine learning software to improve early detection of breast cancer, has raised US$28 million (€24 million) in a Series C funding round led by New York-based global venture capital and private equity firm Insight Partners to further develop its technology and accelerate commercial growth of the company’s Transpara AI breast care software.
Founded in 2014 by Professor Nico Karssemeijer and Professor Sir Michael Brady and based in Nijmegen, the Netherlands, ScreenPoint Medical develops and markets innovative machine learning solutions to improve breast cancer screening and diagnosis. With its market-leading AI solution Transpara, ScreenPoint Medical supports radiologists in evaluating mammograms to detect breast cancer and allows them to improve the quality and efficiency of breast cancer screening. Transpara is currently used in over 200 clinics in 25 countries worldwide.
Insight Partners is a US-based venture capital and private equity firm with more than US$30 billion in capital commitments. With its experience and track record of investing in high-growth technology and software companies that drive transformative change in their industries, Insight Partners is ideally situated to support ScreenPoint Medical with its endeavors. Alongside Insight Partners, University Radiology Group, one of the largest providers of sub-specialty radiology and teleradiology services in the United States, participated in the investment round. Existing investors, including ScreenPoint Medical’s founders Siemens Healthineers and Oost NL, will continue to support the company in its further growth and development.
Oaklins’ team in the Netherlands acted as the exclusive advisor to the shareholders and management of ScreenPoint Medical.
About ScreenPoint
ScreenPoint was founded in 2014 as a spin-off from Radboud University Medical Center in Nijmegen, the Netherlands, to develop and bring to market innovative machine learning solutions to improve breast cancer screening and diagnosis. With an exceptional team of specialists in machine learning, image analysis and breast imaging, ScreenPoint developed the market-leading AI solution Transpara for reading mammograms and breast tomosynthesis.
About Insight Partners
Insight Partners is a leading global venture capital and private equity firm investing in high-growth technology and software ScaleUp companies that are driving transformative change in their industries. Founded in 1995, Insight Partners has invested in more than 400 companies worldwide and has raised through a series of funds more than US$30 billion in capital commitments. Insight's mission is to find, fund and work successfully with visionary executives, providing them with practical, hands-on software expertise to foster long-term success. Across its people and its portfolio, Insight encourages a culture around a belief that ScaleUp companies and growth create opportunity for all.
Nico Karssemeijer
Founder and CEO
Talk to the deal team
Related deals
NetNordic has acquired Itectra
Norvestor-backed NetNordic has acquired Danish optical network solutions firm Itectra. The transaction marks NetNordic’s 25th acquisition since 2015, further strengthening its position in the Nordic market. It enables NetNordic to expand its market relevance through deeper expertise in optical network solutions, consolidating its standing in larger Nordic projects and creating cross-selling opportunities between NetNordic’s network solutions and Itectra’s optical capabilities.
Learn moreLindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn moreMatera has acquired a majority stake in Fáciltech
Matera has acquired a controlling stake in Fáciltech. The acquisition represents a strategic step to expand Matera’s client base and strengthen its core banking offering, incorporating specialized operational management and ERP solutions that serve institutions with different profiles and business models.
Learn more